By Mill Chart
Last update: Mar 4, 2024
Uncover the potential of INTEGRA LIFESCIENCES HOLDING (NASDAQ:IART) as our stock screener's choice for an undervalued stock. NASDAQ:IART maintains a strong financial position and offers an appealing valuation. We'll delve into the specifics below.
ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:IART scores a 8 out of 10:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:IART scores a 7 out of 10:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:IART has received a 5 out of 10:
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:IART has earned a 4 for growth:
More Decent Value stocks can be found in our Decent Value screener.
For an up to date full fundamental analysis you can check the fundamental report of IART
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
INTEGRA LIFESCIENCES HOLDING
NASDAQ:IART (4/19/2024, 7:00:02 PM)
After market: 28.68 0 (0%)28.68
-2.95 (-9.33%)
PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology...
PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company,...
/PRNewswire/ -- Pomerantz LLP is investigating whether the Board of Directors of Integra Lifesciences Holdings Corp (NASDAQ: IART) ("Integra") potentially...
Novel system features flexible tip to deliver flowable version of the Urinary Bladder Matrix (UBM) technology...
Integra LifeSciences CEO, Jan De Witte, plans to retire by end of 2024.
PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the...
Jan De Witte to retire as CEO by the end of 2024Stuart Essig appointed executive chairman of the Board PRINCETON, N.J., Feb. 28, 2024 (GLOBE...
PRINCETON, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company,...
PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company,...